Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2025-08-31 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
第六届董事会第二十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of resolutions passed at the 22nd meeting of the 6th Board of Directors of Beijing Northland Biotechnology Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to amendments in company bylaws and internal management systems. The content focuses on board decisions, governance structure changes, and internal policies, with no financial statements or earnings data. It is not a full annual or interim report, nor an earnings release or audit report. The document is clearly a Board/Management Information announcement about board meeting resolutions and governance matters.
2025-08-31 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Remuneration and Assessment Committee Working Rules" of Beijing Northland Biotechnology Co., Ltd. It details the structure, responsibilities, and procedures of the board committee responsible for remuneration and assessment of directors and senior management. The content is about internal governance rules and committee working procedures rather than financial results, audit opinions, or announcements of voting results. It does not contain financial data or earnings information, nor is it a report or announcement of a report. The document is a governance-related internal rules document. Therefore, it fits best under Governance Information (CGR). The document length is 3257 characters, which is consistent with a detailed governance policy document rather than a brief announcement or report publication notice.
2025-08-31 Chinese
年报信息披露重大差错责任追究制度
Governance Information Classification · 95% confidence The document is titled as a "重大差错责任追究制度" which translates to "Major Error Responsibility Accountability System" related to the annual report information disclosure. It details the company's internal rules and procedures for handling significant errors in annual report disclosures, including responsibilities, standards for identifying major errors, and accountability measures. The content is focused on governance and internal control policies rather than presenting actual financial data or audit results. It does not contain financial statements or substantive financial analysis, nor is it an announcement of a report publication. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-31 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by Beijing Northland Biotechnology Co., Ltd. It details internal company policies, approval procedures, responsibilities, and disclosure requirements related to external guarantees. It includes references to board and shareholder meetings approving these policies but does not contain financial statements, audit results, or financial performance data. The document is a governance-related internal policy document rather than a financial report or announcement. It is not a report publication announcement or a certification. Therefore, it fits best under Governance Information (CGR), which covers company internal rules and governance practices.
2025-08-31 Chinese
累积投票实施细则
Governance Information Classification · 95% confidence The document is titled as the "Implementation Rules for Cumulative Voting" by the company's board and details the procedures and rules for electing directors using cumulative voting. It includes sections on nomination, voting, and election principles for directors, referencing company law and governance rules. There is no financial data, earnings information, or report publication announcement. The content is focused on internal governance procedures related to board elections, which fits the category of Governance Information (CGR). The document length is under 5,000 characters but it is not a brief announcement or a report publication notice; it is a detailed governance policy document. Therefore, the appropriate classification is Governance Information (CGR).
2025-08-31 Chinese
募集资金管理制度
Capital/Financing Update Classification · 95% confidence The document is titled as "募集资金管理制度" which translates to "Fundraising Capital Management System" and details the company's internal policies and procedures for managing raised funds. It includes sections on the storage, use, supervision, and changes in the use of raised capital, as well as the responsibilities of the board and related parties. The document is a detailed internal management system rather than a financial report, earnings release, or announcement of voting results. It is not a regulatory filing or a report publication announcement since it contains substantive content about the company's capital management policies. The document is best classified under Capital/Financing Update (CAP) as it relates to the management and use of capital raised by the company, including compliance with regulatory requirements and internal controls.
2025-08-31 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.